NUWELLIS INC

Investors eye Nuwellis Inc., a Nasdaq‑listed medical device firm targeting fluid overload and heart failure. Despite a steep drop from a $172.90 peak, the company’s niche innovations could drive future growth—watch its next steps for potential upsid…

SEC filing reveals Nuwellis CEO McCormick now owns company shares, underscoring governance strength and commitment to advancing cardiac device innovation.

Nuwellis Inc, a healthcare equipment company specializing in treating fluid overload and heart failure, faces significant financial challenges and market skepticism, but its commitment to addressing critical healthcare needs remains unwavering.

Nuwellis Inc.’s stock performance has been a rollercoaster ride, reflecting both strategic ambitions and market skepticism, as the company navigates financial challenges to advance its commercial-stage medical devices.

Nuwellis Inc.’s stock performance has been a rollercoaster ride, reflecting both strategic ambitions and market skepticism, as the company navigates financial challenges to advance its commercial-stage medical devices.

Nuwellis Inc. is a healthcare company specializing in medical devices that aims to revolutionize cardiac care and improve the quality of life for patients with fluid overload and heart failures.